Neurocrine provides some good news in Huntington’s
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
Neurocrine gets selective in schizophrenia
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Takeda gets the pipeline blues
A big selloff on a mid-stage stumble seems harsh, but Takeda has problems on the horizon.
Cancer continues to dominate deal making
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
Toxicity concerns send Larimar down
The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
